Asian Institute of Gastroenterology   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Hyderabad India (1994)

Organization Overview

First Clinical Trial
2009
NCT01259544
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

AIG Hospitals | Asian Institue of Gastroenterology | Asian Institute of Gastroenterolgy India | Asian Institute of Gastroenterology | ASIAN INSTITUTE OF GASTROENTEROLOGY/AIG HOSPITALS | Asian Institute of Gastroenterology hospitals | Asian Institute of Gastroenterology, Hyderabad, India | Asian Institute of Gastroenterology, India | Asian lnstitute of Gastroenterology

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute-On-Chronic Liver Failure (Phase 3)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Colorectal Neoplasms (Phase 3)

End Stage Liver Disease (Phase 3)

Esophageal Achalasia (Phase 3)

Fatty Liver (Phase 3)

Fibrosis (Phase 4)

Hepatic Insufficiency (Phase 3)

Irritable Bowel Syndrome (Phase 4)

Liver Cirrhosis (Phase 4)

Liver Diseases (Phase 3)

Liver Failure (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 3)

Pancreatitis (Phase 2)

Pancreatitis, Chronic (Phase 2)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 33